Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan

Abstract Objectives This study evaluated the cost‐effectiveness of delgocitinib relative to moisturization therapy in adult patients with moderate to severe atopic dermatitis. Methods The analysis was performed by using the simulation model with the patient‐level data from a phase 3 study and its lo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Motoi Takenaka, Mai Matsumoto, Hiroyuki Murota, Sachie Inoue, Hidetoshi Shibahara, Kazufumi Yoshida, Sotaro Takigawa, Atsushi Ishimoto
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	atopic cost‐benefit analysis delgocitinib dermatitis quality‐adjusted life years Dermatology RL1-803 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/5f2111092a1543278016825af87205d9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5f2111092a1543278016825af87205d9
record_format	dspace
spelling	oai:doaj.org-article:5f2111092a1543278016825af87205d92021-11-08T15:10:52ZCost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan2574-459310.1002/cia2.12163https://doaj.org/article/5f2111092a1543278016825af87205d92021-10-01T00:00:00Zhttps://doi.org/10.1002/cia2.12163https://doaj.org/toc/2574-4593Abstract Objectives This study evaluated the cost‐effectiveness of delgocitinib relative to moisturization therapy in adult patients with moderate to severe atopic dermatitis. Methods The analysis was performed by using the simulation model with the patient‐level data from a phase 3 study and its longterm extension study (QBA4‐1 Study). The analysis was conducted from the Japanese public healthcare payer's perspective and included only direct medical costs. Health outcomes were evaluated by quality‐adjusted life years. The time horizon of the analysis was one year and no discount rate was applied. In this analysis model, health states were divided into four according to the Investigator's Global Assessment score. The cost‐effectiveness was determined by the incremental cost‐effectiveness ratio using the willingness‐to‐pay threshold of 5 million JPY/quality‐adjusted life years. A probabilistic sensitivity analysis was conducted to evaluate the uncertainty of each parameter used for the analysis. Results Total cost and quality‐adjusted life years gained were 358,810 JPY and 0.867 quality‐adjusted life years for delgocitinib, and 85,890 JPY and 0.798 quality‐adjusted life years for moisturization therapy, respectively. The incremental cost‐effectiveness ratio of delgocitinib relative to moisturization therapy was estimated to be 3.92 million JPY/quality‐adjusted life years. The probability of incremental cost‐effectiveness ratio of delgocitinib vs moisturization therapy being below 5 million JPY/quality adjusted life years was 79.1%. Conclusions Delgocitinib was rated as a cost‐effective treatment relative to moisturization therapy in adults with moderate to severe atopic dermatitis. Data comparing the drug for reducing inflammation is required.Motoi TakenakaMai MatsumotoHiroyuki MurotaSachie InoueHidetoshi ShibaharaKazufumi YoshidaSotaro TakigawaAtsushi IshimotoWileyarticleatopiccost‐benefit analysisdelgocitinibdermatitisquality‐adjusted life yearsDermatologyRL1-803Immunologic diseases. AllergyRC581-607ENJournal of Cutaneous Immunology and Allergy, Vol 4, Iss 5, Pp 100-108 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	atopic cost‐benefit analysis delgocitinib dermatitis quality‐adjusted life years Dermatology RL1-803 Immunologic diseases. Allergy RC581-607
spellingShingle	atopic cost‐benefit analysis delgocitinib dermatitis quality‐adjusted life years Dermatology RL1-803 Immunologic diseases. Allergy RC581-607 Motoi Takenaka Mai Matsumoto Hiroyuki Murota Sachie Inoue Hidetoshi Shibahara Kazufumi Yoshida Sotaro Takigawa Atsushi Ishimoto Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan
description	Abstract Objectives This study evaluated the cost‐effectiveness of delgocitinib relative to moisturization therapy in adult patients with moderate to severe atopic dermatitis. Methods The analysis was performed by using the simulation model with the patient‐level data from a phase 3 study and its longterm extension study (QBA4‐1 Study). The analysis was conducted from the Japanese public healthcare payer's perspective and included only direct medical costs. Health outcomes were evaluated by quality‐adjusted life years. The time horizon of the analysis was one year and no discount rate was applied. In this analysis model, health states were divided into four according to the Investigator's Global Assessment score. The cost‐effectiveness was determined by the incremental cost‐effectiveness ratio using the willingness‐to‐pay threshold of 5 million JPY/quality‐adjusted life years. A probabilistic sensitivity analysis was conducted to evaluate the uncertainty of each parameter used for the analysis. Results Total cost and quality‐adjusted life years gained were 358,810 JPY and 0.867 quality‐adjusted life years for delgocitinib, and 85,890 JPY and 0.798 quality‐adjusted life years for moisturization therapy, respectively. The incremental cost‐effectiveness ratio of delgocitinib relative to moisturization therapy was estimated to be 3.92 million JPY/quality‐adjusted life years. The probability of incremental cost‐effectiveness ratio of delgocitinib vs moisturization therapy being below 5 million JPY/quality adjusted life years was 79.1%. Conclusions Delgocitinib was rated as a cost‐effective treatment relative to moisturization therapy in adults with moderate to severe atopic dermatitis. Data comparing the drug for reducing inflammation is required.
format	article
author	Motoi Takenaka Mai Matsumoto Hiroyuki Murota Sachie Inoue Hidetoshi Shibahara Kazufumi Yoshida Sotaro Takigawa Atsushi Ishimoto
author_facet	Motoi Takenaka Mai Matsumoto Hiroyuki Murota Sachie Inoue Hidetoshi Shibahara Kazufumi Yoshida Sotaro Takigawa Atsushi Ishimoto
author_sort	Motoi Takenaka
title	Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan
title_short	Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan
title_full	Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan
title_fullStr	Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan
title_full_unstemmed	Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan
title_sort	cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in japan
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/5f2111092a1543278016825af87205d9
work_keys_str_mv	AT motoitakenaka costeffectivenessanalysisofdelgocitinibinadultpatientswithatopicdermatitisinjapan AT maimatsumoto costeffectivenessanalysisofdelgocitinibinadultpatientswithatopicdermatitisinjapan AT hiroyukimurota costeffectivenessanalysisofdelgocitinibinadultpatientswithatopicdermatitisinjapan AT sachieinoue costeffectivenessanalysisofdelgocitinibinadultpatientswithatopicdermatitisinjapan AT hidetoshishibahara costeffectivenessanalysisofdelgocitinibinadultpatientswithatopicdermatitisinjapan AT kazufumiyoshida costeffectivenessanalysisofdelgocitinibinadultpatientswithatopicdermatitisinjapan AT sotarotakigawa costeffectivenessanalysisofdelgocitinibinadultpatientswithatopicdermatitisinjapan AT atsushiishimoto costeffectivenessanalysisofdelgocitinibinadultpatientswithatopicdermatitisinjapan
_version_	1718442134600679424

Cost‐effectiveness analysis of delgocitinib in adult patients with atopic dermatitis in Japan

Ejemplares similares